| Download | - View final version: Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease (PDF, 7.0 MiB)
- View supplementary information: Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease (DOCX, 4.3 MiB)
|
|---|
| DOI | Resolve DOI: https://doi.org/10.1016/j.jconrel.2024.01.011 |
|---|
| Author | Search for: Caron, Nicholas S.; Search for: Aly, Amirah E.-E.; Search for: Findlay Black, Hailey; Search for: Martin, Dale D. O.; Search for: Schmidt, Mandi E.; Search for: Ko, Seunghyun; Search for: Anderson, Christine; Search for: Harvey, Emily M.; Search for: Casal, Lorenzo L.; Search for: Anderson, Lisa M.; Search for: Rahavi, Seyed M. R.; Search for: Reid, Gregor S. D.; Search for: Oda, Michael N.; Search for: Stanimirovic, Danica1ORCID identifier: https://orcid.org/0000-0001-6678-407X; Search for: Abulrob, Abedelnasser1; Search for: McBride, Jodi L.; Search for: Leavitt, Blair R.; Search for: Hayden, Michael R. |
|---|
| Affiliation | - National Research Council Canada. Human Health Therapeutics
|
|---|
| Format | Text, Article |
|---|
| Subject | Huntington disease; huntingtin lowering; antisense oligonucleotide; apolipoprotein A-I; nanodisks |
|---|
| Abstract | Efficient delivery of therapeutics to the central nervous system (CNS) remains a major challenge for the treatment of neurological diseases. Huntington disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion mutation in the HTT gene which codes for a toxic mutant huntingtin (mHTT) protein. Pharmacological reduction of mHTT in the CNS using antisense oligonucleotides (ASO) ameliorates HD-like phenotypes in rodent models of HD, with such therapies being investigated in clinical trials for HD.
In this study, we report the optimization of apolipoprotein A-I nanodisks (apoA-I NDs) as vehicles for delivery of a HTT-targeted ASO (HTT ASO) to the brain and peripheral organs for HD. We demonstrate that apoA-I wild type (WT) and the apoA-I K133C mutant incubated with a synthetic lipid, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, can self-assemble into monodisperse discoidal particles with diameters <20 nm that transmigrate across an in vitro blood-brain barrier model of HD. We demonstrate that apoA-I NDs are well tolerated in vivo, and that apoA-I K133C NDs show enhanced distribution to the CNS and peripheral organs compared to apoA-I WT NDs following systemic administration. ApoA-I K133C conjugated with HTT ASO forms NDs (HTT ASO NDs) that induce significant mHTT lowering in the liver, skeletal muscle and heart as well as in the brain when delivered intravenously in the BACHD mouse model of HD. Furthermore, HTT ASO NDs increase the magnitude of mHTT lowering in the striatum and cortex compared to HTT ASO alone following intracerebroventricular administration. These findings demonstrate the potential utility of apoA-I NDs as biocompatible vehicles for enhancing delivery of mutant HTT lowering ASOs to the CNS and peripheral organs for HD. |
|---|
| Publication date | 2024-01-24 |
|---|
| Publisher | Elsevier |
|---|
| Licence | |
|---|
| In | |
|---|
| Language | English |
|---|
| Peer reviewed | Yes |
|---|
| Identifier | S0168365924000154 |
|---|
| Export citation | Export as RIS |
|---|
| Report a correction | Report a correction (opens in a new tab) |
|---|
| Record identifier | 6e134cf5-6773-4eef-a3ab-cab1a96d7e17 |
|---|
| Record created | 2024-11-13 |
|---|
| Record modified | 2024-11-13 |
|---|
